COMMUNIQUÉS West-GlobeNewswire

PositiveID’s ExcitePCR Named Major Player in Molecular Diagnostics Industry Report
14/12/2017
DELRAY BEACH, Fla., Dec. 14, 2017 (GLOBE NEWSWIRE) -- PositiveID Corporation (the “Company”) (OTC:PSID), a life sciences company focused on detection and diagnostics, announced today that its ExcitePCR Corporation [...]
India Globalization Capital Provides Update on Hyalolex for Alzheimer’s Commercialization Strategy
14/12/2017
BETHESDA, Md., Dec. 14, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC) today provides an update on corporate initiatives to launch its lead product for Alzheimer’s, Hyalolex, through [...]
Pain Therapeutics Announces New Publication on Alzheimer’s Disease
14/12/2017
AUSTIN, Texas, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE ), a biopharmaceutical company, today announced a new publication for PTI-125, a clinical-stage drug candidate with a novel [...]
Golden Leaf Holdings Opens New Chalice Farms Dispensary in Downtown Portland, Oregon
14/12/2017
PORTLAND, Ore., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (“GLH” or the “Company”) (CSE:GLH) (OTCQB:GLDFF), a leading cannabis oil solutions company and dispensary operator built around recognized [...]
Precipio Files a Patent Application for IV-Cell, its Novel Cytogenetics Media
14/12/2017
NEW HAVEN, Conn., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ: PRPO ), today announced the recent filing of a patent application for IV-Cell, a novel media (reagent) developed by Precipio and validated in [...]
HempAmericana Secures Necessary Raw Inputs for Q1 CBD Oil Production
14/12/2017
NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- HempAmericana, Inc. (OTC:HMPQ) (the “Company”) is excited to confirm that it has secured sufficient necessary raw hemp material for initial production activities to be [...]
Amicus Therapeutics Submits New Drug Application to U.S. FDA for Migalastat for Treatment of Fabry Disease
14/12/2017
CRANBURY, N.J., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD ) submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) to request approval of the oral precision [...]
Mustang Bio to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018
14/12/2017
NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO ), a Fortress Biotech (NASDAQ: FBIO ) company focused on the development of novel immunotherapies based on proprietary chimeric [...]
Fortress Biotech to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018
14/12/2017
NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (“Fortress”) (NASDAQ: FBIO ), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology [...]
Strongbridge Biopharma plc Announces New Employment Inducement Awards
14/12/2017
DUBLIN, Ireland and TREVOSE, Pa., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP ), a global commercial-stage biopharmaceutical company focused on the development and commercialization of [...]
Checkpoint Therapeutics to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018
14/12/2017
NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT ), a Fortress Biotech (NASDAQ: FBIO ) company, today announced that its senior management team will host [...]
Matinas BioPharma Appoints Matthew A. Wikler, M.D., M.B.A., F.I.D.S.A., to Board of Directors
14/12/2017
BEDMINSTER, N.J., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, [...]
Allena Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
14/12/2017
-- Successfully Completed Initial Public Offering, Raising $74.9 Million in Gross Proceeds -- Presented Final Results from Phase 2 Trials of ALLN-177 in Secondary Hyperoxaluria at ASN Kidney Week 2017 -- Received Orphan [...]
Jounce Therapeutics Added to NASDAQ Biotechnology Index
14/12/2017
CAMBRIDGE, Mass., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE ), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers [...]
Microbot Receives Notice of Allowance for U.S. Patent Covering its TipCAT Technology Platform
14/12/2017
HINGHAM, Mass., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT ), a medical device company specializing in the design and development of transformational micro-robotic medical technologies, today [...]
Axsome Therapeutics Collaborates with World-Leading Nicotine Addiction Research Center for Phase 2 Trial of AXS-05 in Smoking Cessation
14/12/2017
Builds on preclinical research conducted at Duke University and clinical research conducted by Axsome Smoking cessation is the third indication for AXS-05 Phase 2 trial initiation anticipated in the first quarter of [...]
HSS and pSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data
14/12/2017
WATERTOWN, Mass. and NEW YORK, Dec. 14, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in the development of sustained release drug delivery products, and Hospital for Special Surgery (HSS), [...]
Akcea Initiates Phase 2 Study of AKCEA-ANGPTL3-LRx in Patients with Hypertriglyceridemia, Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (NAFLD)
14/12/2017
CAMBRIDGE, Mass., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA ), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious [...]
Published Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac Function in an Animal Model of Heart Failure
14/12/2017
IRVINE, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC ), a fully integrated, science-based, nutraceutical company devoted to improving the way people age, announced important cardiac research [...]

Pages